{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:59:23Z","timestamp":1788472763110,"version":"build-2803163510"},"reference-count":29,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hypertrophic cardiomyopathy (HCM) is associated with sudden cardiac death (SCD). The HCM Risk-SCD model has been widely used in Western populations, but its performance in Chinese patients remains unclear. Methods: This retrospective cohort study evaluated 534 HCM patients (348 males and 186 females) at Fuwai Hospital from 1992 to 2010. We calculated the HCM Risk-SCD score for each patient and categorized them into low-risk (&lt;4%) and intermediate\u2013high-risk (\u22654%) groups. The primary endpoint was SCD events, defined as unexpected sudden death within one hour of symptom onset, successful resuscitation after cardiac arrest, appropriate ICD discharge, or sustained ventricular tachycardia. Model performance was assessed using Cox regression analysis, Kaplan\u2013Meier survival analysis, ROC curve analysis, and subgroup analyses with interaction tests. Results: During a mean follow-up of 6.96 \u00b1 4.16 years, 31 SCD events occurred. The intermediate\u2013high-risk group had significantly higher SCD incidence than the low-risk group (8.68% vs. 3.42%, p = 0.01). This association remained significant after multivariate adjustment (HR 2.718, 95% CI: 1.264\u20135.848, p = 0.011). Kaplan\u2013Meier analysis showed significant differences in SCD-free survival between risk strata (log-rank p = 0.01). The actual 5-year SCD event rate (4.31%) closely aligned with the model-predicted rate (4.65 \u00b1 3.26%). ROC analysis demonstrated moderate discriminative ability in the overall population (AUC = 0.660, p = 0.003). The optimal cutoff value was 3.23 for the overall population. Conclusions: The HCM Risk-SCD model demonstrates acceptable performance in Chinese HCM patients.<\/jats:p>","DOI":"10.3390\/jcm14207355","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:29:17Z","timestamp":1760711357000},"page":"7355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of the HCM Risk-SCD Model in a Chinese Hypertrophic Cardiomyopathy Cohort"],"prefix":"10.3390","volume":"14","author":[{"given":"Fei","family":"Hang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaomei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical Course and Management of Hypertrophic Cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","article-title":"Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults","volume":"116","author":"Zou","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.jtcvs.2011.10.020","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"142","author":"Gersh","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CRD.0000000000000612","article-title":"Mechanism of Ion Channel Impairment in the Occurrence of Arrhythmia in Patients with Hypertrophic Cardiomyopathy","volume":"33","author":"Zhang","year":"2025","journal-title":"Cardiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Moore, J., Ewoldt, J., Venturini, G., Pereira, A.C., Padilha, K., Lawton, M., Lin, W., Goel, R., Luptak, I., and Perissi, V. (2023). Multi-Omics Profiling of Hypertrophic Cardiomyopathy Reveals Altered Mechanisms in Mitochondrial Dynamics and Excitation-Contraction Coupling. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054724"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"U\u0161aj, M., Moretto, L., and M\u00e5nsson, A. (2022). Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042195"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/hrt.2010.217182","article-title":"The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy","volume":"98","author":"Lambiase","year":"2012","journal-title":"Heart"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ahj.2013.06.009","article-title":"Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patient outcomes, rate of appropriate and inappropriate interventions, and complications","volume":"166","author":"Vriesendorp","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2012-303271","article-title":"A validation study of the 2003 American College of Cardiology\/European Society of Cardiology and 2011 American College of Cardiology Foundation\/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy","volume":"99","author":"Lambiase","year":"2013","journal-title":"Heart"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"Jichi","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: A report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"f198","DOI":"10.1093\/europace\/eux251","article-title":"Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation","volume":"20","author":"Liebregts","year":"2018","journal-title":"Europace"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/europace\/euv079","article-title":"Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator","volume":"18","author":"Alzueta","year":"2016","journal-title":"Europace"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2016.04.021","article-title":"Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a Reference Center in South America","volume":"118","author":"Quiroga","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","article-title":"Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy","volume":"116","author":"Maron","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"Jichi","year":"2018","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1136\/heartjnl-2019-315160","article-title":"Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians","volume":"105","author":"Choi","year":"2019","journal-title":"Heart"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00380-020-01668-z","article-title":"Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines","volume":"36","author":"Nakano","year":"2021","journal-title":"Heart Vessel."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.hrthm.2020.04.017","article-title":"Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology\/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy","volume":"17","author":"Liu","year":"2020","journal-title":"Heart Rhythm"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dong, Y., Yang, W., Chen, C., Ji, J., Zheng, W., Zhang, F., Yang, B., Li, X., and Zhou, X. (2021). Validation of the 2020 AHA\/ACC risk stratification for sudden cardiac death in Chinese patients with hypertrophic cardiomyopathy. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.691653"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101875","DOI":"10.1016\/j.cpcardiol.2023.101875","article-title":"Validation of the risk stratification for sudden cardiac death in Chinese patients with hypertrophic cardiomyopathy","volume":"48","author":"Qi","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/VHRM.S511689","article-title":"Age and Sex Differences in the Risk of Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy: A Multi-Centre Cohort Study","volume":"21","author":"Ma","year":"2025","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"ref_28","first-page":"880","article-title":"Machine learning in hypertrophic cardiomyopathy: Nonlinear model from clinical and CMR features predicting cardiovascular events","volume":"17","author":"Zhao","year":"2024","journal-title":"Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamacardio.2024.2824","article-title":"Myocardial Scarring and Sudden Cardiac Death in Young Patients with Hypertrophic Cardiomyopathy: A Multicenter Cohort Study","volume":"9","author":"Chan","year":"2024","journal-title":"JAMA Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:00:26Z","timestamp":1760713226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/20\/7355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":29,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14207355"],"URL":"https:\/\/doi.org\/10.3390\/jcm14207355","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}